• Tscan Therapeutics Inc. presented positive data today from Cohort C of its ALLOHAâ„¢ Phase 1 study, evaluating TSC-101 in patients with heme malignancies.
  • 11 of 14 transplanted Cohort C patients achieved complete donor chimerism within approximately three weeks after their first TSC-101 infusion.
  • TSC-101 was generally well-tolerated in Cohort C, with safety consistent with earlier experience.